Memorial Sloan Kettering Cancer Center Update in Hematology and Medical Oncology 2026

1. Overview
The Memorial Sloan Kettering Cancer Center 2026 Update in Hematology and Medical Oncology and 14th Annual Board Review is a four-day comprehensive course offering an in-depth, current review of the diagnosis, staging, and management of neoplastic diseases across both solid tumors and hematologic malignancies. Expert-led lectures cover a wide spectrum of disease-specific topics, including gastrointestinal, gynecologic, thoracic, head and neck, genitourinary, soft tissue and skin, and central nervous system oncology, in addition to hematologic oncology.
Course Date: Friday, March 13, 2026, 9:10 AM – Monday, March 16, 2026, 4:00 PM, Online
This course is designed for medical oncology professionals — including physicians, nurses, pharmacists, advanced practice providers, fellows, and residents — seeking a comprehensive update in Medical Oncology and Hematology.
2. Learning Objectives

Define state-of-the-science in diagnosis, staging, and therapeutic management of solid tumor cancers and hematologic cancers
Discuss recent treatment advances in solid tumor and hematologic oncology and apply knowledge gained in modern clinical practice
Prepare for ABIM examinations in medical oncology and hematology

3. Target Audience

Best for hematologists and medical oncologists who want comprehensive updates on the management of hematologic malignancies and solid tumors.

4. Topics

Acute Lymphocytic Leukemia

Acute Myeloid Leukemia

Anal and Rectal Cancers

Anticoagulation- Update on an Evolving Field

Apporach to the Bleeding Patient

Auto _Allo

Breast Cancer- Radiation Therapy

Breast Cancer- Surgery

CAR T Cell

Carcinoma of Unknown Primary

Central Nervous System Tumors

Chronic Lymphocytic Leukemia _Small Lymphocytic Lymphoma

Chronic Myelogenous Leukemia

Clinical Indications for Use of Blood Products and Associated Risks

Colon Cancer

Diffuse Large B-Cell Lymphoma _Mantle Cell Lymphoma _Burkitt Lymphoma

Esophageal and Gastric Cancers

Head and Neck, Thyroid, and Non-Melanoma Skin Cancers

Hemolytic Anemia

Hepatocellular Cancer and Cholangiocarcinoma

HER2-Positive Breast Cancer

Hereditary Cancer Genetics

Hodgkin Lymphoma_T Cell

Hormone Receptor-Positive Breast Cancer

Infectious Disease

Kidney Cancer

Low-Grade Non-Hodgkin Lymphoma

Melanoma

Mesothelioma

Myelodysplastic

Myeloma_Amyloid

Myeloproliferative Neoplasms

Non-Small Cell Lung Cancer

Ovarian Cancer

Pancreatic and Neuroendocrine Cancers

Pharmacology I_II

Prostate Cancer

Sarcoma

Sickle Cell Disease, Thalassemia

Small Cell Lung Cancer

Testis Cancer

Thrombocytopenia and ITP

Thrombotic Disorders

Transfusion Reactions

Triple-Negative Breast Cancer

Urothelial Cancer

Uterine, Cervix, and Other Gynecologic Cancers

2026 Post-Test HemOnc Board Review